Any COVID-19 vaccine is better than none. But the CDC recommends that people get the Janssen vaccine only if they can’t get the Pfizer/BioNTech or Moderna vaccines.
A small number of very rare but dangerous blood clots linked to the Johnson & Johnson COVID-19 vaccine prompted the Centers for Disease Control and Prevention (CDC) last night to endorse the recommendation of an expert advisory panel in saying that individuals should first try to get the Pfizer/BioNTech and Moderna vaccines. If patients can’t get those, then they should settle for the J&J—or Janssen—vaccine.
Nine deaths have resulted from patients getting a condition called thrombosis with thrombocytopenia (TTS) that have been linked to the J&J vaccine. About 17 million people in the United States have gotten the J&J vaccine. There have been 57 TTS cases altogether.
The recommendation came from the CDC’s Prevention's Advisory Committee on Immunization Practices (ACIP), whose members endorsed the recommendation unanimously.
“Given the current state of the pandemic both here and around the world, the ACIP reaffirmed that receiving any vaccine is better than being unvaccinated,” the CDC said in its recommendation. “Individuals who are unable or unwilling to receive an mRNA vaccine will continue to have access to Johnson & Johnson’s COVID-19 vaccine.”
Of the 57 cases, most occurred in women 18-49 years old, and 36 required treatment in intensive care units. Since April 2021, the rate of TTS has slowly increased to 3.8 per million doses administered. While the condition remains rare, there have been 9 reported deaths so far, 7 in women and 2 in men.
Because the initial regimen only consists of 1 dose, as opposed to 2 shots for the mRNA vaccines, the Janssen vaccine was widely rolled out among populations for whom receiving a multi-dose series would prove more difficult, such as low-income people or people experiencing homelessness.
The CDC emphasized that COVID-19 vaccination is safe and effective, and the vaccines are under the most scrupulous monitoring in US history.
“More than 200 million Americans have completed their primary vaccine series, providing protection against COVID-19, preventing millions of cases and hospitalizations, and saving over a million lives…I continue to encourage all Americans to get vaccinated and boosted," CDC Director Rochelle Walensky, MD, said.
This article first appeared in Contagion®.
Redefining Competency: A Comprehensive Framework for Infection Preventionists
December 19th 2024Explore APIC’s groundbreaking framework for defining and documenting infection preventionist competency. Christine Zirges, DNP, ACNS-BC, CIC, FAPIC, shares insights on advancing professional growth, improving patient safety, and navigating regulatory challenges.
Addressing Post-COVID Challenges: The Urgent Need for Enhanced Hospital Reporting Metrics
December 18th 2024Explore why CMS must expand COVID-19, influenza, and RSV reporting to include hospital-onset infections, health care worker cases, and ER trends, driving proactive prevention and patient safety.
Announcing the 2024 Infection Control Today Educator of the Year: Shahbaz Salehi, MD, MPH, MSHIA
December 17th 2024Shahbaz Salehi, MD, MPH, MSHIA, is the Infection Control Today 2024 Educator of the Year. He is celebrated for his leadership, mentorship, and transformative contributions to infection prevention education and patient safety.
Pula General Hospital Celebrates Clean Hospitals
December 16th 2024Learn how Pula General Hospital in Croatia championed infection prevention and environmental hygiene and celebrated Clean Hospitals Day to honor cleaning staff and promote advanced practices for exceptional patient care and safety.
Understanding NHSN's 2022 Rebaseline Data: Key Updates and Implications for HAI Reporting
December 13th 2024Discover how the NHSN 2022 Rebaseline initiative updates health care-associated infection metrics to align with modern health care trends, enabling improved infection prevention strategies and patient safety outcomes.